Shareholders Would Not Be Objecting To BeiGene, Ltd.'s (NASDAQ:ONC) CEO Compensation And Here's Why
May 15
Have your own idea? Try our Stock Screener
U.S. Biotech Industry Analysis
UpdatedMay 16, 2025
DataAggregated Company Financials
Companies564
- 7D-0.09%
- 3M-11.7%
- 1Y-16.2%
- YTD-8.7%
Over the last 7 days, the Biotech industry has dropped 2.1%, driven by a pullback from AbbVie of 2.1%. On the other hand Regeneron Pharmaceuticals is actually up 6.8%. However, the industry is down 18% over the past year. Looking forward, earnings are forecast to grow by 24% annually.
Industry Valuation and Performance
Has the U.S. Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Fri, 16 May 2025 | US$863.7b | US$155.9b | -US$24,603,386,779.22 | 14.7x | -35.1x | 5.5x |
| Sun, 13 Apr 2025 | US$740.4b | US$119.2b | -US$36,465,001,079.34 | 19.8x | -20.3x | 6.2x |
| Tue, 11 Mar 2025 | US$845.2b | US$118.7b | -US$37,516,362,615.25 | 18.1x | -22.5x | 7.1x |
| Thu, 06 Feb 2025 | US$852.4b | US$117.2b | -US$30,787,020,617.09 | 17.5x | -27.7x | 7.3x |
| Sat, 04 Jan 2025 | US$971.4b | US$149.6b | -US$26,354,792,434.12 | 17x | -36.9x | 6.5x |
| Mon, 02 Dec 2024 | US$1.0t | US$150.0b | -US$26,595,044,865.34 | 16.4x | -39.2x | 6.9x |
| Wed, 30 Oct 2024 | US$898.1b | US$113.4b | -US$36,099,862,624.13 | 20.1x | -24.9x | 7.9x |
| Fri, 27 Sep 2024 | US$885.6b | US$113.2b | -US$36,051,039,342.95 | 21.4x | -24.6x | 7.8x |
| Sun, 25 Aug 2024 | US$908.6b | US$113.2b | -US$35,874,993,723.21 | 23.6x | -25.3x | 8x |
| Tue, 23 Jul 2024 | US$1.2t | US$164.5b | -US$28,074,139,763.44 | 29.1x | -42.5x | 7.3x |
| Thu, 20 Jun 2024 | US$1.1t | US$164.4b | -US$27,969,500,563.98 | 27.2x | -40.6x | 6.9x |
| Sat, 18 May 2024 | US$1.1t | US$164.6b | -US$26,831,179,712.66 | 23.9x | -42.7x | 7x |
| Mon, 15 Apr 2024 | US$1.1t | US$164.3b | -US$23,399,427,407.87 | 21.1x | -46.9x | 6.7x |
| Wed, 13 Mar 2024 | US$1.2t | US$167.3b | -US$22,031,216,768.79 | 18.8x | -54.1x | 7.1x |
| Fri, 09 Feb 2024 | US$1.2t | US$169.3b | -US$26,196,624,627.91 | 19.6x | -44x | 6.8x |
| Sun, 07 Jan 2024 | US$1.4t | US$204.8b | -US$22,501,061,722.00 | 20.5x | -63.1x | 6.9x |
| Tue, 05 Dec 2023 | US$1.3t | US$204.7b | -US$22,047,091,184.00 | 19x | -57.3x | 6.2x |
| Thu, 02 Nov 2023 | US$1.2t | US$207.6b | -US$15,463,681,135.00 | 16.9x | -77.5x | 5.8x |
| Sat, 30 Sep 2023 | US$1.3t | US$207.4b | -US$12,733,898,979.00 | 17.1x | -99.6x | 6.1x |
| Mon, 28 Aug 2023 | US$1.3t | US$207.6b | -US$12,455,656,838.00 | 17.5x | -102.5x | 6.1x |
| Wed, 26 Jul 2023 | US$1.1t | US$186.4b | -US$16,520,100,805.00 | 14.4x | -68.6x | 6.1x |
| Fri, 23 Jun 2023 | US$1.1t | US$186.3b | -US$16,130,651,001.00 | 13.8x | -71.1x | 6.2x |
| Sun, 21 May 2023 | US$1.2t | US$186.0b | -US$15,897,732,960.00 | 12.9x | -72.5x | 6.2x |
| Tue, 18 Apr 2023 | US$1.2t | US$198.4b | -US$3,286,383,305.00 | 13.9x | -359.8x | 6x |
| Thu, 16 Mar 2023 | US$1.1t | US$199.2b | -US$4,736,811,399.00 | 13.1x | -237.9x | 5.7x |
| Sat, 11 Feb 2023 | US$1.2t | US$202.7b | -US$201,937,721.00 | 16.4x | -5723.2x | 5.7x |
| Mon, 09 Jan 2023 | US$1.2t | US$203.3b | US$1.6b | 14.7x | 735.2x | 5.8x |
| Wed, 07 Dec 2022 | US$1.1t | US$202.7b | US$1.4b | 14.8x | 802.1x | 5.6x |
| Fri, 04 Nov 2022 | US$1.1t | US$206.0b | US$7.4b | 14x | 146.7x | 5.2x |
| Sun, 02 Oct 2022 | US$1.0t | US$206.2b | US$5.4b | 14.9x | 189.9x | 4.9x |
| Tue, 30 Aug 2022 | US$1.0t | US$206.2b | US$7.3b | 14.5x | 142x | 5x |
| Thu, 28 Jul 2022 | US$1.1t | US$211.2b | US$11.2b | 16.4x | 96.6x | 5.1x |
| Sat, 25 Jun 2022 | US$1.0t | US$212.4b | US$11.1b | 15.4x | 94.6x | 4.9x |
| Mon, 23 May 2022 | US$1.0t | US$212.3b | US$10.9b | 15.1x | 92.4x | 4.8x |
Price to Earnings Ratio
92.4x
Current Industry PE
- Investors are pessimistic on the American Biotechs industry, indicating that they anticipate long term growth rates will be lower than they have historically.
- The 3-year average PS ratio of 6.3x is higher than the industry's current PS ratio of 5.6x.
Past Earnings Growth
- Total earnings for the Biotechs industry have declined over the last three years, with the industry now making a loss overall.
- Revenues have also declined 9.7% per year, which is driving profits down.
Industry Trends
Which industries have driven the changes within the U.S. Healthcare industry?
| US Market | 4.47% | |
| Healthcare | -2.82% | |
| Biotech | -0.089% | |
| Biotech | -0.089% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| REGN Regeneron Pharmaceuticals | US$584.99 | 6.8% +US$3.9b | -39.6% | PE13.7x | |
| ALNY Alnylam Pharmaceuticals | US$283.40 | 9.7% +US$3.3b | 87.4% | PS15.7x | |
| GILD Gilead Sciences | US$100.34 | 2.2% +US$2.7b | 47.9% | PE20.9x | |
| EXEL Exelixis | US$46.26 | 26.7% +US$2.6b | 117.9% | PE19.6x | |
| VRTX Vertex Pharmaceuticals | US$434.38 | 1.1% +US$1.2b | -1.4% | PS10x |
